Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in North America. In 2018, Lymphoma Canada led a project, which resulted in the development of the first unified national guideline for the front-line treatment of CLL. Lymphoma therapies are funded and regulated are a provincial level, which leaves differing treatment options for lymphoma patients within Canada. National guidelines help provide health-care professionals a standardized evidence-based approach for lymphoma treatment. In 2022, Lymphoma Canada and a group Canadian clinical experts updated these guidelines, which include new and innovative therapeutic options for CLL patients in the frontline setting. Recommendations were provided based on review of available evidence for the first-line treatment of CLL.

Canadian Evidence-based Guideline for the First-line Treatment of Chronic Lymphocytic Leukemia

We would like to express our thanks to the hematologists and medical oncologists who provided their clinical expertise throughout the development of these guidelines:

Dr. Carolyn Owen, Hematologist, Foothills Medical Centre, Alberta.

Dr. Versha Banerji, Hematologist, Cancer Care Manitoba, Manitoba.

Dr. Nathalie Johnson, Hematologist, Jewish General Hospital, Quebec.

Dr. Alina Gerrie, Hematologist, Centre for Lymphoid Cancer, British Columbia.

Dr. Andrew Aw, Hematologist, The Ottawa Hospital, Ontario.

Dr. Christine Chen, Hematologist, University of Toronto, and Princess Margaret Cancer Centre, Ontario.

Dr. Sue Robinson, Hematologist Dalhousie University and QEII Health Sciences Centre, Nova Scotia.


Following the recent publication of Canadian evidence-based guidelines for frontline treatment of chronic lymphocytic leukemia (CLL), the same group of clinicians developed guidelines for CLL in the relapsed/refractory (R/R) setting. The treatment of R/R CLL has changed significantly in the past few years, with many novel therapeutics available to hematologists across the country. These guidelines aim to standardize the management of CLL in the relapsed/refractory setting, using the best evidence currently available.





Follow us on Social Media to stay up to date and informed on all things Lymphoma Canada!